Skip to main content

Table 3 Comparison in general parameters between groups A and B

From: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients

Parameters Group A (n = 22) Group B (n = 45) statistical value P
General information
 Male (cases) 10 23 0.189a 0.664
 Female (cases) 12 22
 Age (years) 63.36 ± 12.42 65.33 ± 12.31 0.613b 0.542
Severity classification of COVID-19    481.5c 0.415
 Mild (cases) 7 19
 Severe (cases) 14 25
 Critical (cases) 1 1
Comorbidities
 Diabetes (cases) 5 6 0.950a 0.330
 Coronary heart disease (cases) 3 7 0.043d 0.836
 Cirrhosis (cases) 0 1 * 1.000
 Biliary infection (cases) 0 1 * 1.000
 Hypothyroidism (cases) 0 1 * 1.000
 Alzheimer’s disease (cases) 0 1 * 1.000
 Nasopharyngeal carcinoma (cases) 0 1 * 1.000
Drugs administered to treat COVID-19
 Lianhua Qingwen capsule 16 30 0.252d  
 Moxifloxacin 12 22 0.189d  
 Arbidol 16 31 0.104d  
 Traditional Chinese Medicine 21 41 *  
  1. a χ2 test. b Student’s t test. c Kruskal-Willis test. d continuous correction χ2 test. * Fisher’s exact test